FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy

Antimicrob Agents Chemother. 2011 Mar;55(3):1312-4. doi: 10.1128/AAC.00589-10. Epub 2010 Dec 13.

Abstract

This is the first case report of Candida glabrata-disseminated candidiasis describing the acquisition of echinocandin resistance following anidulafungin treatment. The initial isolates recovered were susceptible to echinocandins. However, during 27 days of anidulafungin treatment, two resistant strains were isolated (from the blood and peritoneal fluid). The resistant peritoneal fluid isolate exhibited a Ser663Pro mutation in position 1987 of FKS2 HS1 (hot spot 1), whereas the resistant blood isolate displayed a phenylalanine deletion (Phe659).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anidulafungin
  • Antifungal Agents / therapeutic use*
  • Candida glabrata / drug effects*
  • Candida glabrata / enzymology*
  • Candida glabrata / genetics
  • Candidiasis / drug therapy
  • Candidiasis / microbiology
  • Drug Resistance, Fungal / genetics
  • Echinocandins / therapeutic use*
  • Female
  • Glucosyltransferases / genetics*
  • Humans
  • Mutation

Substances

  • Antifungal Agents
  • Echinocandins
  • Anidulafungin
  • Glucosyltransferases